Welcome to our dedicated page for Heartbeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartBeam Inc's SEC filings reveal the regulatory, clinical, and financial developments shaping this development-stage cardiac technology company. As a medical device manufacturer pursuing FDA clearances while building commercial infrastructure, HeartBeam's quarterly 10-Q reports and annual 10-K filings provide detailed disclosure of regulatory submission timelines, clinical study progress, patent portfolio expansion, and cash runway calculations that determine the company's ability to reach commercialization milestones.
The company's 10-K annual reports detail its intellectual property portfolio covering 3D vectorcardiography methods, licensing arrangements, and patent litigation risks. These filings also disclose manufacturing partnerships, quality system compliance, and regulatory inspection outcomes that affect the company's ability to produce and distribute its cardiac monitoring devices. For investors evaluating development-stage medical technology companies, HeartBeam's annual reports outline the specific FDA clearances required before generating significant product revenue.
Form 8-K filings capture material events including FDA decision letters, clinical trial results, partnership agreements, and financing transactions. Given HeartBeam's pre-commercial status, 8-K filings announcing regulatory clearances or clinical study outcomes can significantly impact the company's market valuation. Form 4 insider transaction filings reveal executive and director purchases or sales of company stock, providing insight into management's confidence during different stages of product development and commercialization.
Quarterly 10-Q filings track the company's cash position and operating expenses, helping investors assess whether HeartBeam has sufficient capital to complete regulatory submissions and initial commercialization activities before requiring additional financing. These reports also disclose updates to revenue recognition policies as the company transitions from development activities to commercial sales.
HeartBeam, Inc. reported that on November 20, 2025 it received a Not Substantially Equivalent (NSE) letter from the U.S. Food and Drug Administration regarding its 510(k) application for its 12-Lead Electrocardiogram (ECG) Synthesis Software. An NSE letter means the FDA did not find the device substantially equivalent to a predicate device under this submission. The company stated that it stands behind its clinical data and plans to work with the FDA to reach a resolution. HeartBeam also noted it is evaluating the launch of its novel 3D ECG system, which previously received FDA 510(k) clearance in December 2024.
HeartBeam, Inc. reported third‑quarter results showing a net loss of
Operating expenses were
HeartBeam received FDA clearance in December 2024 for its initial ambulatory ECG system and filed a 510(k) in January 2025 for its 12‑lead synthesis software. It launched an early access program for user feedback and highlighted AI study data supporting arrhythmia classification. Common shares outstanding were 34,340,727 as of September 30, 2025; shares outstanding were 34,443,563 as of November 11, 2025.
HeartBeam, Inc. (BEAT) CFO Tim Cruickshank reported a Form 4 showing a sale of 17,647 shares of Common Stock and a grant of 23,333 Restricted Stock Units (RSUs) on 09/30/2025. The RSUs were issued under the company’s 2022 Equity Incentive Plan and vest in two equal tranches: one half on the three‑month anniversary of the vesting commencement date (July 1, 2025 start) and the remainder on the six‑month anniversary. The filing notes RSUs do not expire and are either vested or canceled. The report was signed by the reporting person on 10/03/2025.
Richard Ferrari, a director of HeartBeam, Inc. (BEAT), filed a Form 4 reporting changes in his beneficial ownership. The filing shows 65,653 shares of common stock held indirectly through the Ferrari Living Trust and a disposition of 179,136 shares. The report also records two restricted stock unit/award grants: 80,645 RSUs awarded on July 11, 2025 and 43,939 RSUs granted on September 30, 2025.
The July RSUs vest 100% on the earlier of July 11, 2026 or the issuer's 2026 annual meeting, subject to continued service as an Outside Director. The September RSUs vest in two tranches: one half at three months and the remainder at six months from the vesting commencement date (July 1, 2025). The July RSUs are described as restricted stock units that do not expire and convert to one share each upon vesting.
HeartBeam, Inc. (BEAT) reporting person George de Urioste disclosed changes in beneficial ownership on 07/11/2025. The filing shows a disposition of 57,146 shares of common stock and a grant of 60,483 restricted stock units (RSUs) that vest 100% on the earlier of 07/11/2026 or the company's 2026 annual meeting, subject to continued service as an Outside Director. The report also lists a derivative position: a special option with a $1.65 exercise price covering 45,454 shares (total underlying common stock shown as 89,454 following the transactions). The RSUs do not expire; the option has exercise and vesting timing described in remarks.
Mark E. Strome, a director of HeartBeam, Inc. (BEAT), reported transactions showing an indirect holding of 3,150,000 shares held by affiliated entities and a direct sale of 57,146 shares on 07/01/2025. The filing states Mr. Strome has authority to vote and dispose of the shares held by Strome Mezzanine Fund II, LP, Mark E. Strome Living Trust, and Strome Dynasty, LLC, and disclaims beneficial ownership except for his pecuniary interest.
The report also discloses equity awards: 60,483 restricted stock units granted on 07/11/2025 that vest on the earlier of 07/11/2026 or the 2026 annual meeting (subject to continued service as an Outside Director), and options covering 36,364 shares with an exercise price of $1.65 (granted 09/30/2025) and a vesting schedule tied to the July 1, 2025 commencement date. The filing is signed by Mr. Strome on 10/02/2025.
Branislav Vajdic, listed as Chief Executive Officer and director of HeartBeam, Inc. (BEAT), reported changes in his beneficial ownership. The filing shows a disposition of 878,664 shares of common stock and reports beneficial ownership of 1,428,424 common shares following the reported transactions. The report also discloses derivative securities: options with a $1.65 exercise price tied to 54,424 underlying common shares and an indicated date of 07/01/2035. An explanatory note states options were granted on September 30, 2025 and vesting occurs in two tranches after a July 1, 2025 vesting commencement date. The form is signed by Mr. Vajdic on 10/02/2025.
Marga Ortigas-Wedekind, a director of HeartBeam, Inc. (BEAT), reported multiple transactions on this Form 4. The filing shows a disposition of 112,293 shares of common stock and remaining beneficial ownership entries including 16,824 shares held indirectly. The reporting person received 60,483 restricted stock units (RSUs) granted on July 11, 2025; those RSUs vest 100% on the earlier of July 11, 2026 or the company’s 2026 annual meeting, subject to continued service as an Outside Director. The filing also discloses a stock option covering 39,394 underlying shares with an exercise price of $1.65 and an indicated post-transaction derivative beneficial ownership total of 83,029 shares. The RSUs are non-expiring (vest or cancel) and the option vesting schedule references a July 1, 2025 commencement with staged vesting.
Willem Elfrink, a director of HeartBeam, Inc. (BEAT), reported transactions dated 07/11/2025 on a Form 4 filed for changes in beneficial ownership. The filing shows 106,825 shares held indirectly by the Elfrink Living Trust and a reported disposition of 351,167 shares of Common Stock. The reporting person received 60,483 restricted stock units (RSUs) on 07/11/2025, which vest 100% on the earlier of 07/11/2026 or the company's 2026 annual meeting if he remains an Outside Director. The filing also discloses stock options covering 45,454 shares with a stated exercise price of $1.65; the explanatory text references a grant on 09/30/2025 and vesting tied to a 07/01/2025 commencement date per the company’s 2022 Equity Incentive Plan. The Form is signed by Mr. Elfrink on 10/02/2025.
HeartBeam, Inc. reported total assets of $5.98 million and combined cash and short-term investments of approximately $5.1 million as of June 30, 2025, with cash and equivalents of $3.26 million. The company recorded a net loss of $4.97 million for the quarter and $10.46 million for the six months ended June 30, 2025, and had an accumulated deficit of $66.73 million. Stockholders' equity was $4.18 million and shares outstanding increased to 34.02 million by June 30, 2025.
R&D expense rose year-to-date as product development and headcount increased while G&A declined. The company completed a February public offering that produced approximately $11.5 million in gross proceeds (about $10.3 million net) and issued shares under an ATM, leaving roughly $15.6 million available under that program. The HeartBeam System received FDA clearance on December 13, 2024; the company filed a 510(k) for its 12-lead synthesis software in January 2025, and its VALID-ECG pivotal study showed 93.4% diagnostic agreement. Management discloses substantial doubt about the company’s ability to continue as a going concern absent additional financing.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
